213 search results for: Pathophysiology
Spotlight on Type 2 Inflammation in the Upper and Lower Airways
In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
This is the full presentation of the March 2025 ADVENT cross-dermatology symposium, hosted in Orlando, Florida, presenting the latest information around type 2 inflammation and its association with atopic dermatitis (AD), prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP).
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
ADVENT On Air | First-hand Experience: Expert Insights on the Management of Atopic Hand and Foot Dermatitis
This podcast episode discusses best practices for the diagnosis of atopic dermatitis of the hands and feet, as well as current and emerging treatment options.
Emerging Perspectives on the Disease Burden and Management of Children With Atopic Dermatitis
This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy
How Biologic Therapy May Lead to Disease Modification in Infants and Children With Atopic Dermatitis
This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.
Charting the Future: Preventing the Atopic March
In this video from the April 2025 WCPD symposium, Dr Eulàlia Baselga discusses how early intervention during infancy and childhood in patients with AD may reduce the progression of the atopic march. Dr Baselga goes on to review data showing how the reduction of biomarkers such as IgE and CCL17 may reduce inflammation and sensitization that contribute to atopic comorbidities.
EAACI PAAM 2025 | How Type 2 Inflammation Shapes a Lifetime
Join ADVENT faculty members Len Bacharier, Antonella Cianferoni, and Andre Moreira for an educational symposium highlighting type 2 inflammation and its shared and distinct roles in multiple chronic pediatric diseases.
